Home > Healthcare > Medical Devices > Diagnostic Devices > Colorectal Cancer Diagnostics Market
The market by test type is categorized into threshold suspend blood test, stool tests, imaging test, biopsy, estimated to reach USD 4.8 billion by 2032 and others. The imaging test is further bifurcated into computed tomography scan, ultrasound, magnetic resonance imaging scan, positron emission tomography scan, colonoscopy, and others. The imaging test segment garnered USD 6.4 billion revenue size in the year 2022.
As a result, the combination of improved accessibility to better treatment and diagnosis, along with the increasing prevalence of colorectal cancer, is projected to drive more patients to visit diagnostics laboratories, ultimately boosting the segment revenue.
Based on end-use, the colorectal cancer diagnostics market is segmented into hospitals, diagnostic imaging centers, cancer research centers, and others. The hospitals segment garnered USD 5.3 billion revenue size in the year 2022. The increasing demand for colorectal cancer screening at hospitals is driven by a multitude of factors as follows;
U.S. colorectal cancer diagnostics market accounted for USD 4.3 billion revenue size in 2022 and is predicted to witness substantial market growth over the analysis timeline. This significant market share is attributable to several factors such as the presence of major business players, an increase in colorectal cancer screening procedures, etc.